Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders

Rhea-AI Summary

Appili Therapeutics announced the results of its annual general meeting held on September 7, 2021, highlighting shareholder approval of all resolutions. Josef Vejvoda has been elected to the Board of Directors, bringing over 25 years of capital markets experience. Voting results indicate strong support for board members, including Ian Mortimer and Brian Bloom, with percentages of votes for exceeding 99%. Additionally, PricewaterhouseCoopers was reappointed as the independent auditor. Appili focuses on developing novel therapies for infectious diseases, including ongoing trials for the antiviral Avigan/Reeqonus.

Positive

• Elected Josef Vejvoda, a capital markets veteran, to the Board, enhancing expertise.
• Shareholder voting results show strong support for board members, indicating confidence.
• Reappointment of PricewaterhouseCoopers as independent auditors suggests financial stability.

Negative

• None.

Capital Markets Veteran Josef Vejvoda to Join Appili Board of Directors as New Director

HALIFAX, Nova Scotia--(BUSINESS WIRE)-- Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced the results from its annual general meeting of shareholders held on Tuesday, September 7, 2021. The Company also announced the addition of Josef Vejvoda to its Board of Directors (the “Board”).

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler, Armand Balboni, and newly elected Josef Vejvoda.

Voting results for each director are summarized below:

Name of Nominee	Percentage of Votes For	Percentage of Votes Withheld
Ian Mortimer	99.85%	0.15%
Brian Bloom	100%	0%
Juergen Froehlich	99.85%	0.15%
Theresa Matkovits	99.85%	0.15%
Rochelle Stenzler	100%	0%
Armand Balboni	100%	0%
Josef Vejvoda	100%	0%

Josef Vejvoda brings to Appili’s Board over 25 years of capital markets experience. Mr. Vejvoda currently acts as special advisor to K2 & Associates Investment Management Inc. (“K2”), a multi-strategy investment fund, and previously held senior operating executive positions at K2 as Chief Compliance Officer and Chief Executive Officer. Mr. Vejvoda has also held senior management roles at a number of the country’s largest financial institutions, including Merrill Lynch Canada, National Bank Financial, and TD Securities, as well as serving on numerous public company boards.

Mr. Vejvoda graduated from Queen’s University with a BSc in Computer Science. Mr. Vejvoda has also earned the Chartered Investment Manager (CIM®) designation from the Canadian Securities Institute and is a graduate of the Institute of Corporate Directors having achieved the ICD.D designation.

Shareholders also approved the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration.

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005350/en/

Media Contacts

Danielle Raabe/APCO Worldwide

T: 1-646-717-9915

Email: DRaabe@apcoworldwide.com

Investor Relations Contacts

Kimberly Stephens, CFO

Appili Therapeutics

E: Info@AppiliTherapeutics.com

Source: Appili Therapeutics Inc.

FAQ

What was the date of the Appili Therapeutics annual general meeting?

The annual general meeting of Appili Therapeutics was held on September 7, 2021.

Who was elected to the Board of Directors of Appili Therapeutics?

Josef Vejvoda was elected to the Board of Directors of Appili Therapeutics.

What percentage of votes did Ian Mortimer receive during the board election?

Ian Mortimer received 99.85% of votes during the board election.

What is the stock symbol for Appili Therapeutics?

The stock symbol for Appili Therapeutics is APLIF.

What firm was reappointed as the independent auditor for Appili Therapeutics?

PricewaterhouseCoopers was reappointed as the independent auditor for Appili Therapeutics.